| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Microtubules. Cephalomannine, like other taxanes, binds to tubulin and promotes microtubule assembly. This stabilizes microtubules and prevents their depolymerization, leading to cell cycle arrest and apoptosis. Cephalomannine is active in promoting microtubule assembly and shows cytotoxicity in human glial and neuroblastoma cell lines.
|
|---|---|
| ln Vitro |
Cephalomannine shows cytotoxicity in human glial and neuroblastoma cell lines. It is active in promoting microtubule assembly. It has antitumor and antiproliferative properties. As a taxane derivative, its mechanism of action is similar to paclitaxel. Cephalomannine shows cytotoxicity in human glial and neuroblastoma cell lines.
|
| ln Vivo |
Cephalomannine has been shown to have antitumor effects in mice. It is used in preclinical research to study taxane-based chemotherapy, structure-activity relationships, and mechanisms of drug resistance. Specific in vivo study details are not provided. Cephalomannine has been shown to have antitumor effects in mice.
|
| Enzyme Assay |
Specific protocols for in vitro enzyme/receptor binding assays for Cephalomannine are not detailed. Its activity is typically assessed in cell-based assays measuring cytotoxicity and microtubule polymerization. Binding to tubulin can be studied using in vitro polymerization assays. Cephalomannine is active in promoting microtubule assembly.
|
| Cell Assay |
Cellular assays for Cephalomannine involve treating cancer cell lines with the compound and assessing cell viability and proliferation. Its ability to promote microtubule assembly can also be studied in cell-free systems or in cells using immunofluorescence. Cephalomannine shows cytotoxicity in human glial and neuroblastoma cell lines.
|
| Animal Protocol |
In vivo efficacy of Cephalomannine has been studied in mouse models of cancer, where it showed antitumor effects. It is used in preclinical research to study taxane-based chemotherapy. Cephalomannine has been shown to have antitumor effects in mice.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Cephalomannine is not available in the provided references. As a taxane derivative, its PK properties are likely similar to other taxanes, with poor oral bioavailability and extensive metabolism.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Cephalomannine is not available. As a taxane derivative, it is expected to have a similar toxicity profile to paclitaxel, which can include myelosuppression, neuropathy, and hypersensitivity reactions.
|
| References |
|
| Additional Infomation |
Taxol B has been reported to exist in Taxus sumatrana, Taxus cuspidata, and other organisms with relevant data. Cefganlonine is a diterpenoid taxane extracted from the bark and leaves of Taxus brevifolia and can be converted into Taxol. (National Cancer Institute, USA)
Cephalomannine is a research compound not approved for clinical use. It is a natural product and a taxane derivative used to study the mechanisms of taxane-based chemotherapy and drug resistance. It is structurally related to paclitaxel. Cephalomannine is a natural taxane diterpenoid closely related to paclitaxel, isolated from the bark and leaves of the yew tree (Taxus species). |
| Molecular Formula |
C45H53NO14
|
|---|---|
| Molecular Weight |
831.912
|
| Exact Mass |
831.346
|
| CAS # |
71610-00-9
|
| PubChem CID |
6436208
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
929.5±65.0 °C at 760 mmHg
|
| Melting Point |
139-141ºC
|
| Flash Point |
516.0±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
6.59
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
60
|
| Complexity |
1790
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C/C=C(\C)/C(=O)N[C@@H](C1=CC=CC=C1)[C@H](C(=O)O[C@H]2C[C@]3([C@H]([C@H]4[C@@]([C@H](C[C@@H]5[C@]4(CO5)OC(=O)C)O)(C(=O)[C@@H](C(=C2C)C3(C)C)OC(=O)C)C)OC(=O)C6=CC=CC=C6)O)O
|
| InChi Key |
DBXFAPJCZABTDR-WBYYIXQISA-N
|
| InChi Code |
InChI=1S/C45H53NO14/c1-9-23(2)39(52)46-33(27-16-12-10-13-17-27)34(50)41(54)58-29-21-45(55)38(59-40(53)28-18-14-11-15-19-28)36-43(8,30(49)20-31-44(36,22-56-31)60-26(5)48)37(51)35(57-25(4)47)32(24(29)3)42(45,6)7/h9-19,29-31,33-36,38,49-50,55H,20-22H2,1-8H3,(H,46,52)/b23-9+/t29-,30-,31+,33-,34+,35+,36-,38-,43+,44-,45+/m0/s1
|
| Chemical Name |
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-3-[[(E)-2-methylbut-2-enoyl]amino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
|
| Synonyms |
NSC318735 NSC 318735 NSC 318735
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~120.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2021 mL | 6.0103 mL | 12.0205 mL | |
| 5 mM | 0.2404 mL | 1.2021 mL | 2.4041 mL | |
| 10 mM | 0.1202 mL | 0.6010 mL | 1.2021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
